Summary
Lesions in such chronic neurodegenerative disorders as Alzheimer disease, Parkinson disease, the parkinsonism dementia complex of Guam and amyotrophic lateral sclerosis have associated with them a variety of proteins known to be involved in inflammatory processes. This is particularly true of Alzheimer disease where inflammatory reactions are thought to be important contributors to the neuronal loss. They include complement proteins, complement inhibitors, acute phase reactants, inflammatory cytokines, proteases and protease inhibitors. Studies of cultured human astrocytes and microglia, obtained from postmortem brain, have established that nearly all of these proteins are produced by one or another of these cell types. Human neurons also produce many inflammatory proteins and their inhibitors, creating complex interactions. Accumulations of amyloid and extracellular tangles apparently act as irritants, causing the activation of complement, the initiation of reactive changes in microglia, and the release of potentially neurotoxic products. Such products include the membrane attack complex, oxygen free radicals and excess glutamate. Twenty epidemiological studies that have been published to data indicate that populations taking antiinflammatory drugs have a significantly reduced prevalence of Alzheimer disease or a slower mental decline. One small clinical trial with indomethacin showed arrest of the disease over a 6 month period. Thera peutic intervention in key inflammatory processes holds great promise for the amelioration of Alzheimer disease and possibly other neurodegenerative disorders.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Akiyama H, Tooyama I, Kondo H, Ikeda K, Kimura H, McGeer EG, McGeer PL (1994) Early response of brain resident microglia to kainic acid-induced hippocampal lesions. Brain Res 635: 257–268
Breitner JCS, Gau BA, Welsh KA, Plassman BL, McDonald WM, Helmas MJ, Anthony JC (1994) Inverse association of anti-inflammatory treatments and Alzheimer’s disease. Neurology 44: 227–232
Breitner JCS, Welsh KA, Helms MJ, Gaskell PC, Gau BA, Roses AD, Pericak-Vance MA, Saunders AM (1995) Delayed onset of Alzheimer’s disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs. Neurobiol Aging 16: 523–530
Doraiswamy PM, Krishen A, Stallone F, Martin WL, Potts NLS, Metz A, DeVeaugh-Geiss J (1996) NSAIDs and cognition in Alzheimer’s disease. Neurology 46: 1994
Graham DY, Agrawal NM, Roth SH (1988) Prevention of NSAID-induced gastric ulcer with misoprostol: multicentre, double-blind, placebo-controlled trial. Lancet ii: 1277–1280
Klegeris A, McGeer PL (1994) Rat brain microglia and peritoneal macrophages show similar responses to respiratory burst stimulants. J Neuroimmunol 53: 83–90
Klegeris A, McGeer PL (1997) β-Amyloid protein and glutamine enhance macrophage production of oxygen free radicals and glutamate. J Neurosci Res 49: 229–235
Laskin DL, Pendino KJ (1995) Macrophages and inflammatory mediators in tissue injury. Ann Rev Pharmacol Toxicol 35: 655–677
McGeer PL, Rogers J (1992) Anti-inflammatory agents as a therapeutic approach to Alzheimer’s disease. Neurology 42: 447’449
McGeer PL, McGeer EG (1995) The inflammatory system of brain: implications for therapy of Alzheimer and other neurodegenerative disorders. Brain Res Rev 21: 195–218
McGeer EG, McGeer PL (1997) Inflammatory cytokines in the CNS. CNS Drugs 7: 214–228
McGeer PL, Schulzer M, McGeer EG (1996) Arthritis and antiinflammatory agents as negative risk factors for Alzheimer disease: a review of seventeen epidemiological studies. Neurology 47: 425–432
Ostbye T, Crosse E (1994) Net economic costs of dementia in Canada. Can Med Assoc J 151: 1457–1464
Pasinetti GM, Johnson SA, Rozovsky I, Lampert-Etchells M, Morgan DG, Gordon MN, Morgan TE, Willoughby D, Finch CE (1992) Complement C1qB and C4 mRNAs responses to lesioning in rat brain. Exp Neurol 118: 117–125
Rich JB, Rasmusson DX, Folstein MF, Carson KA, Kawas C, Brandt J (1995) Nonsteroidal anti-inflammatory drugs in Alzheimer’s disease. Neurology 45: 51–55
Rogers J, Kirby LC, Hempelman SR, Berry DL, McGeer PL, Kaszniak AW, Zalinski J, Cofield M, Mansukhani L, Willson P, Kogan F (1993) Clinical trial of indomethacin in Alzheimer–s disease. Neurology 43: 1609–1611
Roses AD (1996) Apolipoprotein E alleles as risk factors in Alzheimer–s disease. Ann Rev Med 47: 387–400
Shen Y, Li R, McGeer EG, McGeer PL (1997) Neuronal expression of mRNAs for complement proteins of the classical pathway in Alzheimer brain. Brain Res 769: 391–395
Stewart WF, Kawas C, Corrada M, Metter EJ (1997) Risk of Alzheimer’s disease and duration of NSAID use. Neurology 48: 626–63
Taupenot L, Ciesielski-Traska J, Ulrich G, Chasserot-Golaz S, Aunis D, Bader MF (1996) Chromogranin A triggers a phenotypic transformation and the generation of nitric oxide in brain microglial cells. Neuroscience 72: 377–389
Terai K, Matsuo A, McGeer PL (1996) Enhancement of immunoreactivity for NF-κB in the hippocampal formation and cerebral cortex of Alzheimer’s disease. Brain Res 735: 159–168
Walker DG, Kim SU, McGeer PL (1995) Complement and cytokine gene expression in cultured microglia derived from postmortem human brains. J Neurosci Res 40: 478–493
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Springer-Verlag/Wien
About this paper
Cite this paper
McGeer, P.L., McGeer, E.G. (1998). Mechanisms of cell death in Alzheimer disease — immunopathology. In: Gertz, HJ., Arendt, T. (eds) Alzheimer’s Disease — From Basic Research to Clinical Applications. Journal of Neural Transmission. Supplementa, vol 54. Springer, Vienna. https://doi.org/10.1007/978-3-7091-7508-8_15
Download citation
DOI: https://doi.org/10.1007/978-3-7091-7508-8_15
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-83112-0
Online ISBN: 978-3-7091-7508-8
eBook Packages: Springer Book Archive